Journals / Kocaeli Tıp Dergisi / 2021 / Cilt: 10 - Sayı: 2

Prognostic Factors in Membranous Nephropathy Patients

Membranöz Nefropatili Hastalarda Prognostik Faktörler

Pages
167–173
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the remission group, female gender was higher (p=0.022), diastolic blood pressure was lower (p=0.025), mycophenolate use was less (p=0.019), serum creatinine was lower (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:INTRODUCTION: Membranous nephropathy (MN) is the most common cause of nephrotic syndrome (NS) in adults.
📊
Key Findings & Data:In our study, we aimed to determine the factors affecting remission in patients with MN at the end of the first year METHODS: Our retrospective study was performed on patients over 18 years of age diagnosed with MN between 2015-2018.
💡
Conclusion & Impact:In the remission group, female gender was higher (p=0.022), diastolic blood pressure was lower (p=0.025), mycophenolate use was less (p=0.019), serum creatinine was lower (p
🔬Design:Research Article
📍Scope:2015-2018 Verileri
⚙️Variables:Domain Parameters

Abstract

INTRODUCTION: Membranous nephropathy (MN) is the most common cause of nephrotic syndrome (NS) in adults. In our study, we aimed to determine the factors affecting remission in patients with MN at the end of the first year METHODS: Our retrospective study was performed on patients over 18 years of age diagnosed with MN between 2015-2018. In MN patients, baseline, 6th, 12th-month laboratory values (serum albumin, proteinuria, eGFR) and treatment response at the end of the 12th month was evaluated. RESULTS: Forty-three MN patients (24 (55.8%) women) with a mean age of 42.2±12.5 were evaluated. MN patients were divided into two groups at the end of the 12-month treatment period, remission and non-remission. In the remission group, female gender was higher (p=0.022), diastolic blood pressure was lower (p=0.025), mycophenolate use was less (p=0.019), serum creatinine was lower (p

Özet

GİRİŞ ve AMAÇ: Membranöz nefropati (MN) yetişkinlerde nefrotik sendromun (NS) en yaygın nedenidir.Çalışmamızda MN’li hastalarda 1. yıl sonunda remisyonu etkileyen faktörleri belirlemeyi amaçladık. YÖNTEM ve GEREÇLER: Retrospektif çalışmamız, 2015-2018 yılları arasında MN tanısı almış, 18 yaş üstü hastalar üzerinde gerçekleştirildi. Hastalara ait tüm veriler hastanemiz medikal kayıtlarından elde edildi. MN hastaların başlangıç, 6., 12. ay laboratuvar değerleri (serum albümin, proteinüri, eGFR) ve 12. ay sonunda tedavi yanıt durumu değerlendirildi.. BULGULAR: Çalışmamızda ortalama yaşı 42.2±12.5 olan 24(%55.8)’u kadın 43 MN’li hasta üzerinde gerçekleştirildi. Hastalar 12 aylık tedavi süresinin sonunda remisyona giren (22, %51.2) ve girmeyen (21, %48.8) olmak üzere 2 gruba ayrıldı. Remisyon grubunda kadın cinsiyet daha fazla (p = 0,022), diyastolik kan basıncı daha düşük (p=0,025), mikofenolat kullanımı daha az (p=0,019), serum kreatinin daha düşük (p

🔖

Cite This Article

KAYA, B., PAYDAŞ, S., KUZU, T., BALAL, M. (2022). Prognostic Factors in Membranous Nephropathy Patients. Kocaeli Tıp Dergisi, Cilt: 10 - Sayı: 2, 167–173. https://ajindex.com/articles/652968

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011
  2. 26(2):414-30. 2.Turkmen A, Sumnu A, Cebeci E, Yazici H, Eren N, Seyahi N, et al. Epidemiological features of primary glomerular disease in Turkey: a multicenter study by the Turkish Society of Nephrology Glomerular Diseases Working Group. BMC Nephrol. 2020
  3. 21(1):481. 3.Donadio JV, Jr., Torres VE, Velosa JA, Wagoner RD, Holley KE, Okamura M, et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int. 1988
  4. 33(3):708-15. 4.Beck LH, Jr., Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009
  5. 361(1):11-21. 5.Tomas NM, Beck LH, Jr., Meyer-Schwesinger C, SeitzPolski B, Ma H, Zahner G, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014
  6. 371(24):2277-87. 6.Sethi S, Debiec H, Madden B, Charlesworth MC, Morelle J, Gross L, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2020
  7. 97(1):163-74. 7.Wasserstein AG. Membranous glomerulonephritis. J Am Soc Nephrol. 1997
  8. 8(4):664-74. 8.Sprangers B, Bomback AS, Cohen SD, Radhakrishnan J, Valeri A, Markowitz GS, et al. Idiopathic membranous nephropathy: clinical and histologic prognostic features and treatment patterns over time at a tertiary referral center. Am J Nephrol. 2012
  9. 36(1):78-89. 9.Tu WH, Petitti DB, Biava CG, Tulunay O, Hopper J, Jr. Membranous nephropathy: predictors of terminal renal failure. Nephron. 1984
  10. 36(2):118-24. 10.Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2012
  11. 2(suppl 2): 139–274. 11.Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019
  12. 95(2):268-80. 12.Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010
  13. 55(4):622-7. 13.Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH, et al. KDOQI US commentary on the 2012 KDI